Hormone-Balancing Effect Of Pre-Gelatinized Organic Maca (Lepidium Peruvianum Chacon): (II) Physiological And Symptomatic Responses Of Early-Postmenopausal Women To Standardized Doses Of Maca In Double Blind, Randomized, Placebo-Controlled, Multi-Centre Clinical Study
|Values||(ng/ml). PMM: Baseline: 0.425 Placebo: 0.510 Maca: 0.472 MMP: baseline: 0.541 Placebo: 0.331 Maca: 0.574|
|Trial Design||Randomized trial|
|Trial Length||1-6 months|
|Number of Subjects||102|
In a randomized, double-blind, placebo-controlled trial, 102 healthy postmenopausal women were assigned to take 2 g of maca daily for 2 months, and placebo for one month. They were separated into two groups, one that received placebo first, followed by two months of maca, or two months of maca followed by placebo.Funding issues for this study:
Follicle-stimulating hormone was reduced somewhat while on maca in the group that received the placebo first, which was statistically significant, and was reduced in the maca-first group, but one month on placebo only saw a small increase, the difference not being statistically significant. Estradiol was increased significantly while on maca in the placebo-first group and increase in the maca-first group, though the reduction after placebo was small and didn't return to baseline, the difference not being statistically significant. There were no significant changes in progesterone, luteinizing hormone, total cholesterol, LDL, and triglycerides, though a significant increase in HDL in the maca-first group.
Menopausal symptoms were reduced significantly in both groups while on maca, both on Kupperman’s Menopausal Index and Greene’s Menopausal Score. There were significant improvements in hot flushes, excessive sweating, interrupted sleep, nervousness on the first test, and nervousness, concentration, fatigue, lack of interesting, being unhappy/depressed, irritability, loss of consciousness, nervous tension, headaches, hot flushes, night sweating, muscle, and joint aches and pains, and lack of libido in the second.
Afterwards maca and placebo were given intermittently to 66 participants for 4 months, in 4 different schedules: (P=placebo, M=MACA): PMMP, PPMM, MMPP, and MMPM. Symptoms were reduced significantly in all groups on Kupperman's Menopausal Index, but only in the PPMM group for Green's Menopausal Score.
"This study was conducted and jointly supported by a long-term joint R&D program of the Research Institute of Medicinal Plants (RIMP) in Poznan, Poland and School of Health Study, Charles Sturt University & Therapeutic Research International, Sydney, Australia on medicinal plants and therapeutic preparations originating in Australasia, Oceania and South America. Thanks are due to Ms. Dorota R. Meissner of Therapeutic Research International for assistance in collecting results from clinics and diagnostic laboratories in Poland including help in compilation and formatting data for computation and data processing as well as Ms. Jan Roberts for assistance in editing of the final draft. A supply of a standardized Maca-GO powder by NatureCorp Pty Ltd, Australia for encapsulation in RIMP, is gratefully acknowledged."